Anti-IGF-IR antibodies and uses thereof
AssigneePierre Fabre Medicament
InventorsLiliane Goetsch, Nathalie Corvaia
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR). The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR, stimulated either by IGF1 and/or IGF2, or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or the IGF-I/Insulin hybrid receptor.
Claims5
An isolated nucleic acid, selected from the group consisting of:
- a) a nucleic acid coding for an antibody that specifically binds insulin-like growth factor 1 receptor (IGF-1R), or an antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof comprises:
- (i) a heavy chain comprising three CDRs of sequence SEQ ID NOS:
- 2, 4 and 6, and (ii) a light chain comprising three CDRs of sequence SEQ ID NOS:
- 1, 3 and 5;
- b) a nucleic acid comprising three CDRs of sequence SEQ ID NOS:
- 9, 10 and 11, and/or three CDRs of sequence SEQ ID NOS:
- 12, 13 and 14;
- c) a nucleic acid comprising the light chain of sequence SEQ ID NO:
- 15 and/or the heavy chain of sequence SEQ ID NO:
- 16;
- and
- d) a nucleic acid comprising the light chain of sequence SEQ ID NO:
- 19 and/or the heavy chain of sequence SEQ ID NO:
- 20.
Dependencies are inferred from the claim text.